MilliporeSigma has announced the winners of its Advance Biotech Grant programme in North America.
MilliporeSigma (Burlington, Massachusetts, USA) has announced the winners of its Advance Biotech Grant programme in North America. The grant is given to small- and mid-size biotechnology companies that need funding and expertise to get their therapies to market. Applicants were asked to describe their projects, the medical needs they solve, and process development challenges they face to be considered for the grant. In support of the growing biotech ecosystem, grant recipients receive between $40,000 and $100,000 in MilliporeSigma products and process development support.
“With more than 60 percent of drugs in the pipeline today being developed by biotechs, we are committed to supporting these startâups in developing ground-breaking therapeutics,” said Udit Batra, CEO, MilliporeSigma. “Our global grant programme provides free access to our process development expertise, products, and services to help accelerate molecule-to-market efforts.”
The three winners are: RAFT Pharmaceuticals (San Diego, California), for its approach to treat chronic pain using a biologic to selectively inhibit neuroinflammation without affecting normal motor or sensory function; Rubicon Biotechnology (Anaheim, California), for developing a therapeutic protein, Fv-Hsp72, designed to protect and salvage cells damaged from an acute event, such as traumatic brain injury; and TechnoVax Inc (Elmsford, New York), for developing a virus-like particle platform that facilitates the development and production of a range of vaccines targeting the prevention of respiratory diseases, haemorrhagic fevers, immunodeficiency, and cancers.
For more information, please visit www.emdgroup.com
The Next Frontier for Mass Spectrometry: Maximizing Ion Utilization
January 20th 2025In this podcast, Daniel DeBord, CTO of MOBILion Systems, describes a new high resolution mass spectrometry approach that promises to increase speed and sensitivity in omics applications. MOBILion recently introduced the PAMAF mode of operation, which stands for parallel accumulation with mobility aligned fragmentation. It substantially increases the fraction of ions used for mass spectrometry analysis by replacing the functionality of the quadrupole with high resolution ion mobility. Listen to learn more about this exciting new development.
Using Chromatography to Explore Fluorescent Bioactive Compounds in the Coelomic Fluid of Earthworms
February 6th 2025A study aiming to identify fluorescent bioactive compounds in the coelomic fluid of earthworms, as well as to investigate their structural and functional characteristics for possible use in biomedical applications, utilized a variety of chromatographic techniques.
The Complexity of Oligonucleotide Separations
January 9th 2025Peter Pellegrinelli, Applications Specialist at Advanced Materials Technology (AMT) explains the complexity of oligonucleotide separations due to the unique chemical properties of these molecules. Issues such as varying length, sequence complexity, and hydrophilic-hydrophobic characteristics make efficient separations difficult. Separation scientists are addressing these challenges by modifying mobile phase compositions, using varying ion-pairing reagents, and exploring alternative separation modes like HILIC and ion-exchange chromatography. Due to these complexities, AMT has introduced the HALO® OLIGO column, which offers high-resolution, fast separations through its innovative Fused-Core® technology and high pH stability. Alongside explaining the new column, Peter looks to the future of these separations and what is next to come.